ICICI Prudential Nifty Pharma Index Fund Direct Reinvestment Inc Dist cum Cap Wdrl

ICICI Prudential Nifty Pharma Index Fund Direct Reinvestment Inc Dist cum Cap Wdrl is an equity fund. This fund was started on 15 December, 2022. The fund is managed by Nishit Patel. The fund could potentially beat inflation in the long-run.

1. ICICI Prudential Nifty Pharma Index Fund Direct Reinvestment Inc Dist cum Cap Wdrl has ₹84 Cr worth of assets under management (AUM) as on Jun 2025 and is more than category average.
2. The fund has an expense ratio 0.4.
   

ICICI Prudential Nifty Pharma Index Fund Direct Reinvestment Inc Dist cum Cap Wdrl has given a CAGR return of 23.54% since inception. Over the last 1 year the fund has given a CAGR return of 12.02%.

ICICI Prudential Nifty Pharma Index Fund Direct Reinvestment Inc Dist cum Cap Wdrl has allocated its funds majorly in Cash Equivalent, Health. Its top holdings are Sun Pharmaceuticals Industries Ltd, Divi's Laboratories Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd, Lupin Ltd

As it is a index funds mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 20%
For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefit
Dividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.

The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.

Minimum investment for lump sum payment is INR 1000.00 and for SIP is INR 1000.00. ICICI Prudential Nifty Pharma Index Fund Direct Reinvestment Inc Dist cum Cap Wdrl has no lock in period.